Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (4): 38-44.doi: 10.6040/j.issn.1671-7554.0.2021.1381

Previous Articles    

Efficacy of additional idebenone in the treatment of 34 patients with Parkinsons disease with depression

ZHAO Hailong1,2, WANG Hao2, FANG Yuqing2, MAO Fei2, ZHAO Zhangning2, TIAN Xiangqi2, XU Xinrong2, WANG Min3, LI Xiuhua2   

  1. 1. Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang 261000, Shandong, China;
    2. Department of Neurology, The First Affiliated Hospital of Shandong Frist Medical University &
    Shandong Provincial Qianfoshan Hospital, Shandong Institute of Neuroimmunology, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan 250014, Shandong, China;
    3. Key Laboratory of Animal Resistance Biology of Shandong Province, College of Life Science, Shandong Normal University, Jinan 250014, Shandong, China
  • Published:2022-04-22

PDF (PC)

49

Abstract: Objective To observe the efficacy of idebenone in the treatment of Parkinsons disease with depression(PDD), and to explore its neuroprotective mechanism. Methods A total of 68 PDD patients were randomly divided into control group(n=34)and observation group(n=34). The control group received oral Dobasil tablets and Piribedil sustained-release tablets for 12 weeks. The initial dose of Dobasil tablets was 0.125 g/time, 3 times a day, and the highest dose was ≤0.75 g/d. The initial dose of Piribedil sustained-release tablets was 50 mg/time, once a day, and the maximum dose was 50 mg/time, 3 times a day. The observation group received oral idebenone plus the same treatment as the control group for 12 weeks. The dose was 30 mg/time, 3 times a day. The changes of Hamilton Depression Scale(HAMD)and its factor scores, Hamilton Anxiety Scale(HAMA)and its factor scores, Unified Parkinsons Scale-Ⅲ(UPDRS-Ⅲ), Parkinsons Disease Sleep Scale(PDSS), Mini Mental State Examination Scale(MMSE), 39-item Parkinsons Disease Questionnaire(PDQ-39)and superoxide dismutase(SOD)in the peripheral blood were monitored in the two groups. Results After treatment, the total score of HAMD and all factors in both groups were decreased. Except for weight loss and diurnal changes, the total score of HAMD and the scores of anxiety/somatization, cognitive impairment, block, sleep disorder and despair were significantly lower in the observation group than in the control group(P<0.05). The total score of HAMA and the scores of mental anxiety and somatic anxiety were decreased in both groups(P<0.05), and were significantly lower in the observation group than in the control group(P<0.05). The scores of UPDRS-Ⅲ were decreased in both groups(P<0.05), and were significantly lower in the observation group than in the control group(P<0.05). The PDSS scores were increased in both groups(P<0.05), and were significantly higher in the observation group than in the control group(P<0.05). The MMSE scores were increased in both groups(P<0.05), and were significantly higher in the observation group than in the control group(P<0.05). The PDQ-39 scores were decreased in both groups(P<0.05), and were significantly lower in the observation group than in the control group(P<0.05). The level of SOD was increased in the observation group but decreased in the control group, and the difference was statistically significant(P<0.05). Conclusion Additional idebenone can improve the depression, motor and some non-motor symptoms, increase the level of SOD in peripheral blood and improve the quality of life.

Key words: Parkinsons disease, Depression, Idebenone, Motor symptom, Non-motor symptom

CLC Number: 

  • R574
[1] Prell T, Witte OW, Grosskreutz J. Biomarkers for dementia, fatigue, and depression in Parkinson disease [J]. Front Neurol, 2019, 10: 195. doi:10.3389/fneur.2019.00195.
[2] Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review [J]. JAMA, 2020, 323(6): 548-560.
[3] Schrag A, Taddei RN. Depression and anxiety in Parkinsons disease [J]. Int Rev Neurobiol, 2017, 133: 623-655. doi: 10.1016/bs.irn.2017.05.024.
[4] Malpartida AB, Williamson M, Narendra DP, et al. Mitochondrial dysfunction and mitophagy in Parkinsons disease: from mechanism to therapy [J]. Trends Biochem Sci, 2021, 46(4): 329-343.
[5] Dorszewska J, Kowalska M, Prendecki M, et al. Oxidative stress factors in Parkinsons disease [J]. Neural Regen Res, 2021, 16(7): 1383-1391.
[6] Petschner P, Gonda X, Baksa D, et al. Genes linking mitochondrial function, cognitive impairment and depression are associated with endophenotypes serving precision medicine [J]. Neuroscience, 2018, 370: 207-217. doi:10.1016/j.neuroscience.2017.09.049.
[7] Bang Y, Lim J, Choi HJ. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinsons disease: clues to early diagnosis and effective treatment [J]. Arch Pharmacal Res, 2021, 44(6): 588-604.
[8] Gueven N, Woolley K, Smith J. Border between natural product and drug: comparison of the related benzoquinones idebenone and coenzyme Q10 [J]. Redox Biol, 2015, 4: 289-295. doi:10.1016/j.redox.2015.01.009.
[9] Erb M, Hoffmann-Enger B, Deppe H, et al. Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I [J]. PLoS One, 2012, 7(4): e36153.
[10] Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinsons disease [J]. Febs J, 2018, 285(19): 3657-3668.
[11] Rocha EM, de Miranda B, Sanders LH. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinsons disease [J]. Neurobiol Dis, 2018, 109(Pt B): 249-257. doi: 10.1016/j.nbd.2017.04.004.
[12] Ludtmann MHR, Abramov AY. Mitochondrial calcium imbalance in Parkinsons disease [J]. Neurosci Lett, 2018, 663: 86-90. doi: 10.1016/j.neulet.2017.08.044.
[13] Grinberg LT, Rueb U, Alho ATDL, et al. Brainstem pathology and non-motor symptoms in PD [J]. J Neurol Sci, 2010, 289(1/2): 81-88.
[14] Park JS, Davis RL, Sue CM. Mitochondrial dysfunction in Parkinsons disease: new mechanistic insights and therapeutic perspectives [J]. Curr Neurol Neurosci Rep, 2018, 18(5): 21.
[15] Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinsons disease-an evidence-based medicine review [J]. Mov Disord, 2019, 34(2): 180-198.
[16] 陈海波, 陈生弟, 李淑华. 帕金森病抑郁、焦虑及精神病性障碍的诊断标准及治疗指南[J]. 中华神经科杂志, 2013, 46(1): 56-60.
[17] 张晓韬, 何天齐, 朱梅佳, 等. 艾地苯醌联合治疗帕金森病疗效的临床观察[J]. 山东大学学报(医学版), 2019, 57(4): 34-41. ZHANG Xiaotao, HE Tianqi, ZHU Meijia, et al. Clinical observation of the effects of idebenone on Parkinsons disease [J]. Journal of Shandong University(Health Sciences), 2019, 57(4): 34-41.
[18] Upneja A, Paul BS, Jain D, et al. Anxiety in Parkinsons disease: correlation with depression and quality of life [J]. J Neurosci Rural Pract, 2021, 12(2): 323-328.
[19] 刘瑜. 艾地苯醌联合常规药物治疗帕金森病疗效的临床观察[J]. 中国医药指南, 2020, 18(29): 97-98. LIU Yu. Clinical observation on the efficacy of idebenone combined with conventional drugs in the treatment of Parkinsons disease [J].Guide of China Medicine, 2020, 18(29): 97-98.
[20] Khatri DK, Choudhary M, Sood A, et al. Anxiety: an ignored aspect of Parkinsons disease lacking attention [J]. Biomed Pharmacother, 2020, 131: 110776. doi:10.1016/j.biopha.2020.110776.
[21] 马惠姿, 房进平, 冯涛, 等. 帕金森病患者不同程度抑郁在汉密尔顿抑郁量表的结构差异[J]. 中国康复理论与实践, 2021, 27(7): 829-833. MA Huizi, FANG Jinping, FENG Tao, et al. Structural differences of depression for patients with Parkinsons disease using Hamilton depression scale [J]. Chinese Journal of Rehabilitation Theory and Practice, 2021, 27(7): 829-833.
[22] 夏秋怡, 徐茂青, 霍青. 艾地苯醌结合美多芭对帕金森患者的疗效、步态及精神状态的影响[J]. 卒中与神经疾病, 2020, 27(5): 627-630. XIA Qiuyi, XU Maoqing, HUO Qing. The effects of idebenone combined with medoba on the curative effect, gait and mental state of patients with Parkinsons disease [J]. Stroke and Nervous Diseases, 2020, 27(5): 627-630.
[23] Jaber SM, Ge SX, Milstein JL, et al. Idebenone has distinct effects on mitochondrial respiration in cortical astrocytes compared to cortical neurons due to differential NQO1 activity [J]. J Neurosci, 2020, 40(23): 4609-4619.
[24] 杨硕, 赵丹鹏, 李琳, 等. 艾地苯醌对帕金森患者额叶磁共振波谱成像的影响[J]. 中国合理用药探索, 2019, 16(2): 124-126. YANG Shuo, ZHAO Danpeng, LI Lin, et al. Effect of idebenone on magnetic resonance spectroscopy imaging of frontal lobes in patients with Parkinsons disease [J]. Chinese Journal of Rational Drug Use, 2019, 16(2): 124-126.
[25] 徐珍. 艾地苯醌辅助治疗帕金森病疗效观察[J]. 临床合理用药杂志, 2020, 13(14): 35-37.
[26] Hanganu A, Degroot C, Monchi O, et al. Influence of depressive symptoms on dopaminergic treatment of Parkinsons disease[J]. Front Neurol, 2014, 5: 188. doi:10.3389/fneur.2014.00188.
[27] 黄骥, 阳军, 欧阳娟, 等.艾地苯醌联合多巴丝肼治疗帕金森病的临床研究[J].药物评价研究, 2020, 43(12):2501-2504. HUANG Ji, YANG Jun, OU Yangjuan, et al. Clinical study on idebenone combined levodopa and benserazide hydrochloride in treatment of Parkinsons disease [J]. Drug Evaluation Research, 2020, 43(12): 2501-2504.
[28] Avcı B, Günaydın C, Güvenç T, et al. Idebenone ameliorates rotenone-induced Parkinsons disease in rats through decreasing lipid peroxidation [J]. Neurochem Res, 2021, 46(3): 513-522.
[29] He Y, Tian YL, Han H, et al. The path linking disease severity and cognitive function with quality of life in Parkinsons disease: the mediating effect of activities of daily living and depression [J]. Heal Qual Life Outcomes, 2021, 19(1): 92.
[30] Lubomski M, Davis RL, Sue CM. Health-related quality of life for Parkinsons disease patients and their caregivers [J]. J Mov Disord, 2021, 14(1): 42-52.
[31] 康蓓, 慕生枝, 李妮妮, 等. 艾地苯醌联合多巴丝肼治疗帕金森病的疗效及对氧化应激因子的影响[J]. 山西医药杂志, 2019, 48(16): 1958-1960. KANG Bei, MU Shengzhi, LI Nini, et al. Efficacy observation of idebenone combined with levodopa and its effect on oxidative stress level in patients with Parkinsons disease [J]. Shanxi Medical Journal, 2019, 48(16): 1958-1960.
[32] Yan AJ, Liu ZH, Song L, et al. Idebenone alleviates neuroinflammation and modulates microglial polarization in LPS-Stimulated bv2 cells and MPTP-Induced Parkinsons disease mice [J]. Front Cell Neurosci, 2018, 12: 529. doi: 10.3389/fncel. 2018.00529.
[1] ZHAO Xuan, LI Xiaopeng, LI Jian, TIAN Bin, WANG Guangjun. Therapeutic effects of auricular points sticking with magnetic beads combined with repeated transcranial magnetic stimulation on post-stroke depression [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 65-70.
[2] FU Wenhao, LI Jiajia, FANG Feng, LI Shixue. Depression status and associated factors among informal caregivers of patients with critical illness [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 71-77.
[3] SUN Fuyun, WANG Weipeng, ZHANG Huihui, GENG Yan, AN Xiaoxia, LI Shuangshuang, ZHANG Binbin. Correlation among personality traits and depression, anxiety symptoms in patients after colorectal cancer resection [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 91-96.
[4] Ping LIU,Yuwen SONG,Ping WANG,Guangwei TIAN,Fengjie ZHENG,Li LYU,Jiaojiao DU,Jing ZHANG,Xianghua ZHUANG,Shihong CHEN. Correlation between vitamin D deficiency and depression in patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 51-56,102.
[5] LI Ning, WANG Cuilan, ZHANG Yurong. Association analysis of cerebral artery Doppler index and serum EGF level with arteriosclerosis and cognitive impairment in 60 patients with Parkinsons disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 61-66.
[6] LI Xiangqing, YIN Xin, ZHAO Xuelian, ZHAO Peiqing. Expression and clinical significance of circulating CD56bright subset of NK cells in patients with Parkinsons disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 34-40.
[7] WANG Wei, YANG Yongqin, MI Guolin. Comparison of the efficacy of escitalopram alone and with Qi Yang Yu Xin Dan Fang in the treatment of female depression with sexual dysfunction [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 97-101.
[8] YU Huihui, LEI Zhen, WANG Shukang, PAN Fang. Negative emotion and related factors in elderly patients with comorbidity of hypertension and diabetes [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(12): 81-85,96.
[9] LI Qin1, JIAO Zhi'an2, ZHAO Guoqing2, GAO Jin2. Comparison of the effects between escitalopram and venlafaxine on the social function in patients with depression [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(5): 104-108.
[10] DING Juan, JIANG Hong, PAN Fang. Association of the marital quality and psychological stress in patients with epilepsy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(8): 99-102.
[11] CHANG Xue-run1,2, SUN Xiu-bin1, LIU Yan-xun1, YUAN Zhong-shang1, ZHANG Jing-xuan2, XUE Fu-zhong1. Prevalence of depression symptoms and its risk factors in the rural residents of Laiwu City [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(7): 96-99.
[12] WEI Qian-qian1, JIAO Zhi-an2, GAO Jin2, ZHAO Guo-qing2. Effects of anxiety symptoms on the treatment of depression [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 113-117.
[13] YUAN Hai-peng1,2， LI Fu-kang2, LI Gai-qin2, WANG Xiao-hong2, LI Xiao-pei2, LI Yan-qing1. Relationship between psychosocial factors and duodenal mast cells in
patients with functional dyspepsia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(6): 122-.
[14] DU Jin-ling1， LIU De-xiang1， CHEN Wen-qiang2， JIANG Hong1， ZHANG Qian1， Pan Fang1. Stress responses and related factors of patients with coronary
heart disease after coronary intervention [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 131-.
[15] LI Xin1, ZHANG Jing-xuan2, TANG Ji-sheng2. A matched-control study on coping styles of
patients with major depression [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 135-140.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24 -29 .
[2] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30 -37 .
[3] SHAO Na, YIN Hao, LI Yaran, ZHANG Baokun, HUANG Weiwei, LU Shanshan, TANG Jiyou. Study on the mechanism of Suvorexant treatment ameliorates learning and memory impairment in chronic sleep deprivation mice model[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 17 -23 .
[4] XU Ge, LI Qing, ZHANG Cancan, TIAN Yongjie. Expressions and clinical significance of PARP-1 and HIF-1α in adenomyosis tissues and primary cells[J]. Journal of Shandong University (Health Sciences), 0, (): 55 -61 .
[5] LI Honghao, YU Jing, CHEN Yali, GUO Shougang. Evaluation of CD4+CD25+FoxP3+ regulatory T cells and FoxP3 mRNA expression in 20 NMOSD patients[J]. Journal of Shandong University (Health Sciences), 0, (): 50 -54 .
[6] YANG Congpin, LUO Zhuoye, XU Xiuhua, LI Aimin, HAO Guimin. Reproductive choices and pressure in 3,512 women of childbearing age in a hospital in Hebei Province[J]. Journal of Shandong University (Health Sciences), 0, (): 62 -67 .
[7] LIU Liwen, MA Jun, LI Peizheng, ZHANG Xiufang, LIU Yiming. Caregiver burden and influencing factors of 128 patients with Parkinsons disease[J]. Journal of Shandong University (Health Sciences), 0, (): 45 -49 .
[8] SUN Jiye, WANG Ziou, SUN Xiaowei, LI Hongtao. Effects of traditional Chinese medicine fumigation combined with extracorporeal shock wave therapy on 72 cases of femoroacetabular impingement syndrome and serum inflammatory factor[J]. Journal of Shandong University (Health Sciences), 0, (): 76 -81 .
[9] SHEN Yufei, ZHAO Mei, HU Mi. Help-seeking willingness, help-seeking behaviors and influencing factors in middle school students with suicidal ideation[J]. Journal of Shandong University (Health Sciences), 0, (): 99 -106 .
[10] YUAN Hongtao, JI Congshan, KANG Bing, QIN Songnan, YU Xinxin, GAO Lin, WANG Ximing. Diagnostic value of CT radiomics nomogram for adrenal lipid-poor adenoma and nodular hyperplasia[J]. Journal of Shandong University (Health Sciences), 0, (): 68 -75 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd